Expression of human full-length MUC1 inhibits the proliferation and migration of a B16 mouse melanoma cell line

FENGLI WANG*, QIONGSHU LI*, WEIHUA NI, FANG FANG1,2, XIAXIA SUN1, FEI XIE1, JUAN WANG1, FANG WANG1, SUJUN GAO3 and GUIXIANG TAI1

1Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021; 2Department of Immunology, Jilin Medical College, Jilin 132013; 3Department of Hematology and Oncology, The First Bethune Hospital of Jilin University, Changchun 130021, P.R. China

Received January 7, 2013; Accepted March 26, 2013

DOI: 10.3892/or.2013.2440

Abstract. Mucin 1 (MUC1) is a large transmembrane glycoprotein that is aberrantly overexpressed in most adenocarcinomas and certain hematological malignancies. MUC1 is known to function as an oncogene with roles in both tumor formation and progression, making it a potential target for immunotherapy. B16-MUC1 cells with human full-length MUC1 are frequently used to study the antitumor activities of MUC1-based vaccines. However, we found that the growth of B16-MUC1 cells was significantly reduced in vitro. Therefore, in this study, we established two MUC1-positive clones, B16-MUC1 9-12 and B16-MUC1 9-23, and one empty vector control clone, B16-neo, to investigate the effects of MUC1 on the cancer-related characteristics of B16 cells in vitro and in vivo. Our results demonstrated that, compared with MUC1-negative cells, cells expressing MUC1 exhibited decreased cell proliferation, increased cell cycle arrest and reduced cell migratory and invasive capacities. We further investigated several MUC1-related molecules of the β-catenin pathway, and found that the expression of MUC1 decreased the translocation of β-catenin into the nucleus, reduced the activity of T cell factor (TCF) and blocked the expression of cyclin D1 and c-Myc. Moreover, when inoculated into BALB/c nude mice, cells expressing MUC1 developed smaller tumors compared with the control cells. These results demonstrate that MUC1 expression negatively affects the malignancy of B16 cells, and suggest that the regulatory mechanisms of MUC1 as an oncprotein are more complex than previously appreciated.

Introduction

Mucin 1 (MUC1) is a transmembrane glycoprotein that is expressed in most epithelial cells and is aberrantly overexpressed in many types of human adenocarcinomas and hematologic malignancies (1). MUC1 consists of a large extracellular N-terminal subunit and a C-terminal subunit that resides on the cell surface as a heterodimeric complex via strong noncovalent interactions. The N-terminal subunit consists of a variable number of 20-amino acid tandem repeats (VNTR) that comprise the majority of the extracellular domain. The C-terminal subunit is composed of a 58-amino acid extracellular domain, a 28-amino acid transmembrane domain (TM) and a 72-amino acid cytoplasmic tail (CT) (2-4). The MUC1-CT is highly conserved among different species and possesses 7 tyrosine residues that can be potentially phosphorylated by multiple kinases (5-8); this region also associates with certain transcription factors (9-11). Available evidence indicates that the MUC1-CT is involved in many signaling pathways, including the Wnt/β-catenin (5,12,13), p53 (9,11) and NF-κB (14) pathways. β-catenin, a major effector of the Wnt signaling pathway, interacts with the MUC1-CT at an SXXXXXXSSLS site. This interaction blocks GSK3β-induced degradation of β-catenin and promotes the translocation of β-catenin to the nucleus, where it forms complexes with the LEF/TCF (lymphoid enhancer factor/T cell factor) transcription factors and activates transcription of Wnt-responsive genes such as cyclin D1 and c-Myc to regulate cell proliferation (15,16).

Previous studies have shown that MUC1 plays a role in a diverse array of cellular processes including differentiation (17) motility or inhibition of cell-cell and cell-matrix adhesion (18-21) and immune regulation (22). Recently, the majority of studies have shown that the MUC1-CT contributes to malignant transformation as an oncoprotein. Overexpression of the MUC1-CT in 3Y1 fibroblasts induced cellular transformation and promoted tumor formation in nude mice (23). Mutation of the MUC1-CT (Y46F, Y60F) abrogated MUC1-induced anchorage-independent growth and tumorigenicity in human...
colon carcinoma cells (24,25). Inhibition of the MUC1-CT induced cancer cell death and tumor regression (26,27). The deletion of MUC1 expression from MMTV-Wnt-1 transgenic mice resulted in a significant increase in the time to mammary gland tumor onset (28). However, several studies have shown an inverse association between MUC1 and cell proliferation and adhesion. For example, Hattrup and Gendler (29) and Costa et al (30) demonstrated that MUC1 downregulation in human BT20 breast carcinoma cells or human gastric carcinoma MKN45 cells increased proliferation. Considering these contradictory findings, the role of MUC1 in cancer progression has yet to be clarified.

In this study, we investigated the effects and related mechanisms of MUC1 on cancer-related characteristics of B16 cells by stable expression of the human full-length MUC1 in B16 cells. We found that MUC1 expression in B16 cells inhibited cell proliferation, decreased cell migration and invasion, and suppressed tumor growth in BALB/c nude mice. These results suggest that the modulatory effects of MUC1 in tumor cells may be more complex than previously appreciated, which reinforces the importance of understanding alternative regulatory mechanisms of MUC1.

Materials and methods

Cell line, plasmids and animals. The B16 cell line was purchased from ATCC (Manassas, VA, USA) and cultured in Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum (FBS) (Gibco-BRL, Carlsbad, CA, USA) in a humidified atmosphere of 5% CO₂ at 37°C. The pcDNA3-MUC1 plasmid, which contains the full-length human MUC1 consisting of 22 TR, was a gift from Dr O.J. Finn of the University of Pittsburgh (Pittsburgh, PA, USA). BALB/c nude mice (4-6 weeks old) were purchased from Vital River Laboratories (Vital River, China). Animals were maintained in specific pathogen-free conditions and were fed sterile water and food ad libitum. All animals were treated in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and with the approval of the Scientific Investigation Board of Science and Technology of Jilin Province.

Cell transfection. B16 cells growing in an exponential phase were seeded in a 6-well plate. When cells reached 80-90% confluence, 1.0 µg of pcDNA3-MUC1 plasmid was transfected with Lipofectamine™ 2000 (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. Two stable MUC1-positive clones (B16-MUC1 9-12, B16-MUC1 9-23) were selected in 1,000 µg/ml G418 (Gibco-BRL), and the concentration was decreased to 600 µg/ml to maintain filtrate efficacy. Meanwhile, a negative control B16-neo cell line was prepared by transfecting the pcDNA3 empty vector into the B16 cells.

Reverse transcription-polymerase chain reaction (RT-PCR). MUC1, cyclin D1 and c-Myc mRNA levels were analyzed by RT-PCR. Total RNA was extracted from cells using Trizol reagent (Invitrogen Life Technologies). Total RNA was converted to cDNA using M-MLV reverse transcriptase and Oligo(dT) primers (Promega Corporation, Madison, WI, USA) according to the manufacturer’s protocol. The reverse transcribed products were used to amplify MUC1, cyclin D1 and c-Myc by PCR using Ex-Taq DNA polymerase (Takara Bio, Inc., Shiga, Japan), and β-actin was used as an internal control gene. The primer sequences and reaction parameters are shown in Table I. Amplified products were analyzed on a 1.5% agarose gel, and DNA was visualized by a Gel Image System (Tanon). The final value was expressed as a ratio of the relative density of the target gene to β-actin from three independent experiments (means ± SD).

Flow cytometry. To analyze MUC1 expression of stable transfectants, cells (1x10⁶) were fixed with paraformaldehyde for 1 h and washed twice with fluorescence-activated cell sorter (FACS) solution (PBS containing 2% FCS and 0.1% NaN₃). Subsequently, the cells were incubated with a mouse monoclonal antibody against MUC1 tandem repeats (HMPV; BD Biosciences, Franklin Lakes, NJ, USA) on ice for 30 min, washed twice with FACS solution and stained with fluorescein

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Primers (5'-3', forward and reverse)</th>
<th>Annealing temperature (°C)</th>
<th>Cycles</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human MUC1</td>
<td>Forward: 5'-TGAGTGTAGTGCCATTTCC-3' Reverse: 5'-CTGCCGTAGTTCTTTCG-3'</td>
<td>56</td>
<td>30</td>
<td>158</td>
</tr>
<tr>
<td>Mouse β-actin</td>
<td>Forward: 5'-TGTCCACCTTTCCCAGAGATG-3' Reverse: 5'-AGCTCGTAAACAGTTCCGCTAG-3'</td>
<td>54</td>
<td>25</td>
<td>101</td>
</tr>
<tr>
<td>Mouse cyclin D1</td>
<td>Forward: 5'-AGCAGAAGTGCAGAAGAG-3' Reverse: 5'-GCAGTCAAGGGAATGGTGTC-3'</td>
<td>52</td>
<td>30</td>
<td>154</td>
</tr>
<tr>
<td>Mouse c-Myc</td>
<td>Forward: 5'-AAGGGAAAGACGATGACGG-3' Reverse: 5'-TGAGAAACCCTCCACATA-3'</td>
<td>52</td>
<td>40</td>
<td>172</td>
</tr>
</tbody>
</table>
isothiocyanate (FITC)-conjugated goat anti-mouse secondary antibody (Proteintech Group, Chicago, IL, USA) at a dilution of 1:100 for 30 min on ice in the dark. After washing twice with FACS solution, the expression of MUC1 was analyzed by flow cytometry (FACSCalibur; BD Biosciences).

**Immunofluorescence.** Cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. After blocking with 2% bovine serum albumin (BSA), the cells were incubated with a mouse anti-MUC1 monoclonal antibody (GP1.4, NeoMarkers) overnight at 4°C. After washing, PE-conjugated goat anti-mouse IgG (Proteintech Group) was added for 1 h at 37°C in the dark. The nuclei were stained with 1 µg/ml 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, MO, USA) for 10 min, and the cells were visualized using an inverted fluorescence microscope (Olympus, IX71). Tumors were fixed in 10% neutral-buffered formalin and embedded in paraffin. Serial paraffin sections (5-µm) were cut and mounted on slides for immunofluorescence staining. Sections were treated with 1.5% rabbit serum at 37°C for 30 min. Following that, the sections were incubated with primary antibody GP1.4 and PE-conjugated goat anti-mouse IgG as described above. The nuclei were stained with DAPI and the sections were visualized by inverted fluorescence microscopy.

**Cell proliferation assay.** Cell viability was determined using a WST-1 cell proliferation assay according to the manufacturer's protocol (Roche Diagnostics, Mannheim, Germany). Briefly, cells (5x10^3/well) were seeded in triplicate in 96-well plates and cultured at 37°C with 5% CO_2 in a humidified atmosphere for 96 h. WST-1 reagent was added at 24, 48, 72 or 96 h, and incubation was continued for an additional 1-2 h. Then, the absorbance was measured using a microplate reader at a wavelength of 450 nm (BioTek Instruments, Inc., Winooski, VT, USA). The resulting values were calculated as a ratio of B16-MUC1 to B16-neo and were the average from three independent experiments (means ± SD).

**Cell cycle analysis.** Cells (1x10^6) were harvested and then permeabilized with 70% ice-cold ethanol on ice for 30 min. Cells were then washed and incubated in staining buffer with 50 µg/ml propidium iodide (PI), 10 µg/ml RNase A and 0.1% Triton X-100 for 30 min in the dark. Subsequently, the cell cycle was analyzed by flow cytometry (FACSCalibur; BD Biosciences).

**Cell migration and invasion assay.** Cell migration and Matrigel invasion assays were performed using Transwell chambers with 8-µm pore size filters (Corning Incorporated, Corning, NY, USA) coated with or without Matrigel matrix (BD Biosciences) in a 24-well plate. In each well, 6x10^4 cells were seeded to the upper chamber in 200 µl IMDM containing 1% FBS, and 600 µl IMDM containing 10% FBS was added to the bottom chamber as a chemoattractant. The cells were incubated at 37°C in a 5% CO_2 atmosphere and allowed to migrate or invade for 36 h. Following the incubation period, the remaining cells in the upper chamber were removed gently with a cotton swab. The cells on the lower surface of the chamber were fixed with methanol for 20 min, and then stained with 1% crystal violet in 20% methanol for 30 min. The cells that had migrated or invaded through the filters were counted in five random fields under a microscope.

**Coimmunoprecipitation analysis.** B16-MUC1 cells were lysed with RIPA lysis buffer containing 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS), 0.1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethyl sulfonyl fluoride (PMSF), 0.23 U/ml aprotinin, and 10 μM leupeptin (Sigma-Aldrich). Protein concentrations were measured using a BCA protein assay kit (Bio-Rad Laboratories). Protein aliquots were subjected to immunoprecipitation with 1.0 μg of mouse IgG or anti-MUC1-CT antibody (Ab-5; NeoMarker) for 16 h at 4°C followed by precipitation with Protein G agarose beads (Prozyme Corporation). Immunoprecipitated proteins and total cell lysates were resolved by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected to immunoblot analysis with anti-β-catenin (1:1000; BD Biosciences) for 16 h at 4°C. Following incubation, the reactivity was detected with horseradish peroxidase-conjugated secondary antibodies (1:2000; Sigma-Aldrich) and ECL reagents (GE Healthcare).

** Luciferase reporter assay.** Cells were seeded in 6-well plates. When cells reached 90% confluence, 1.0 μg of TOPflash and FOPflash plasmids (Upstate Biotechnology, Inc., Lake Placid, NY, USA) were transiently transfected with Lipofectamine™ according to the manufacturer's instructions. To normalize the transfection efficiency, the cells were cotransfected with 0.05 μg of pRL-TK (Promega Corporation). Forty eight hours post-transfection, the luciferase assay was performed with the Dual Luciferase Assay System kit (Promega Corporation). Relative luciferase activity was calculated as the fold induction after normalization for transfection efficiency.

**Western blot analysis.** Cells were lysed with RIPA lysis buffer as described above. Nuclear and cytoplasmic protein extracts were isolated using a cytoplasmic and nuclear protein extraction kit (Thermo Scientific) according to the manufacturer's protocol. Protein concentrations were measured using a BCA protein assay kit (Biorad). Protein concentrations were measured using a BCA protein assay kit (Biorad). Equal amounts of protein were separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA), and the membranes were blocked in 3% BSA overnight at 4°C. The membranes were then incubated with primary antibodies against MUC1 (GP1.4) (1:2000), c-Myc (1:1000), cyclin D1 (1:1000; both from Epitomics, Burlingame, CA, USA), β-catenin (1:1000; BD Transduction Labs) or E-cadherin (1:800, Proteintech) for 2 h at room temperature, with the antibodies against β-actin (1:2000), Il6β (1:2000) and Lamin B1 (1:2000; all from Epitomics) as loading controls. Then, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:2000; Sigma-Aldrich) for another 2 h at room temperature. The membranes were developed using ECL reagents (GE Healthcare). Each experiment was repeated at least 3 times.

**In vivo tumor growth assays.** To determine the effects of MUC1 expression on tumorigenesis in vivo, BALB/c female
nude mice (4-6 weeks old) were used to establish a subcutaneous transplant tumor model. Mice were randomly divided into 2 groups (5 animals/group) that were designated as the B16-neo group and the B16-MUC1 group. B16-MUC1 cells or B16-neo cells (2x10^6) were subcutaneously injected into the right flank of each mouse. Tumor size was measured by calipers every 2 days. On day 12 post injection, the tumors were removed and weighed.

**Statistical analysis.** All statistical analyses were performed using unpaired Student’s t-tests, and P<0.05 was considered to indicate a statistically significant result.

**Results**

**Stable MUC1 expression in mouse melanoma B16 cells.** To assess the effects of MUC1 expression, mouse B16 cells were transfected with a vector encoding human full-length MUC1 containing 22 TR (pcDNA3-MUC1) or an empty pcDNA3 vector. Stable transfectants were selected with G418 (1,000 µg/ml) and analyzed for MUC1 expression by RT-PCR, flow cytometry and immunofluorescence. Two MUC1-positive clones (B16-MUC1 9-12 and B16-MUC1 9-23) expressed higher MUC1 mRNA levels and were selected for further study. By contrast, there was no detectable MUC1 expression in the B16-neo cells transfected with the empty vector (Fig. 1A). Flow cytometry (Fig. 1B) and immunofluorescence staining (Fig. 1C) with anti-MUC1 tandem repeat peptide antibodies (HMPV and GP1.4) verified that MUC1 was expressed on the cell surface of 97.0 and 99.0% of B16-MUC1 9-12 and B16-MUC1 9-23 cells, respectively.

**MUC1 expression inhibits cell proliferation and induces G1-phase arrest in vitro.** To determine the effect of MUC1 expression on cell growth in vitro, equal numbers of B16-MUC1, B16-neo and B16 cells were seeded in 96-well plates and cultured for 96 h in a humidified atmosphere of 5% CO₂ at 37°C. Cell viability was evaluated by the WST-1 assay. The results showed that B16-MUC1 cells had a higher percentage of cells in the G0/G1 phase (73.2±2.13%) and fewer in the G2/M phase (2.3±0.39%) when compared with B16-neo cells (61.2±3.34% in G0/G1) or B16 cells (57.68±3.41% in G0/G1) (6.39±1.7% in G2/M) (Fig. 2A and C). These results indicate that MUC1 expression in B16 cells inhibited cell proliferation and induced cell cycle arrest at the G1 phase.

**MUC1 expression inhibits cell migration and invasion in vitro.** To investigate whether MUC1 expression affects the motility of B16 cells, the migratory capacity of cells was evaluated using the Transwell migration assay. The results showed that the number of B16-MUC1 cells that migrated into the lower chamber was significantly decreased when compared to the number of migrating B16-neo or B16 cells (Fig. 3A and B).
We further performed a Matrigel invasion assay to qualitatively observe the effect of MUC1 expression on the invasive potential of cells. The results showed that the number of B16-MUC1 cells that invaded through the Matrigel-coated membrane was also significantly less than the number of invading B16-neo or B16 cells (Fig. 3C and D) (P<0.01). These results show that MUC1 expression inhibited cell migration and invasion in vitro.

MUC1-CT interacts with β-catenin and reduces the activity of T cell factor (TCF). Numerous reports have confirmed that MUC1 binds to β-catenin and is involved in the β-catenin signaling pathway. Therefore, we performed coimmunoprecipitation to investigate whether or not the interaction between MUC1 and β-catenin was also observed in B16-MUC1 cells. Immunoprecipitation of MUC1 from B16-MUC1 cell lysates using anti-MUC1-CT antibody (Ab-5) followed by immunoblot analysis using anti-β-catenin antibody revealed a protein band that co-migrated with β-catenin in total cell lysates; no β-catenin band was detected in the control immunoprecipitates with IgG (Fig. 4A). The results showed that MUC1-CT binds directly to β-catenin in B16-MUC1 cells. Since the Wnt pathway is known to be involved in tumor cell proliferation, to determine the effect of the interaction between the MUC1-CT and β-catenin on the activation of Wnt signaling, a luciferase reporter assay was performed. The results showed that Topflash/Fopflash reporter activity in B16-MUC1 cells was lower than that in the B16-neo cells (P<0.05) (Fig. 4B). The result indicates that the interaction between MUC1-CT and β-catenin reduces the activity of TCF in B16-MUC1 cells when compared with that in the B16-neo cells.

MUC1 expression blocks β-catenin translocation to the nucleus. Since β-catenin is involved in MUC1 signal transduction, to evaluate the effect of MUC1 expression on β-catenin subcellular localization, equivalent protein aliquots of total cell lysates or purified nuclear or cytosolic fractions from cells were immunoblotted with the β-catenin antibody. Immunoblot analysis demonstrated that the total β-catenin levels were unchanged (Fig. 5A), the cytoplasmic β-catenin levels were increased (Fig. 5B) (P<0.05) and the nuclear β-catenin levels were reduced (Fig. 5C) (P<0.05) in B16-MUC1 cells compared to B16-neo or B16 cells. The results indicate that MUC1 expression blocks the translocation of β-catenin to the nucleus. We also analyzed the level of E-cadherin, a molecular chaperone of β-catenin that plays an important role in cell adhesion. The immunoblot results show that E-cadherin expression was slightly upregulated in the MUC1-transfected B16 cells when compared with that of the negative control cells, although there was no statistical significance (Fig. 5D).

MUC1 expression downregulates both cyclin D1 and c-Myc. Nuclear translocation of β-catenin can activate cyclin D1 and c-Myc expression and stimulate cell proliferation. Our results demonstrated that MUC1 expression reduced levels of nuclear β-catenin and inhibited cell proliferation. Therefore, we carried...
out RT-PCR and western blotting to detect the expression of cyclin D1 and c-Myc. The PCR results showed that mRNA levels of cyclin D1 and c-Myc were significantly decreased in the B16-MUC1 cells when compared with levels in the B16 or B16-neo cells (P<0.01 and P<0.05, respectively; Fig. 6A). Immunoblot analysis showed similar results (Fig. 6B). These findings indicate that MUC1 expression downregulated the levels of cyclin D1 and c-Myc.

MUC1 expression suppresses tumor growth in vivo. To evaluate the effects of MUC1 expression on tumorigenesis in vivo, B16-MUC1 and B16-neo cells (2×10⁶) were inoculated subcutaneously into BALB/c nude mice to establish a subcutaneous transplant tumor model. Tumor growth was monitored for 12 days, and the B16-MUC1 tumors grew more slowly than the B16-neo tumors. The B16-MUC1 tumors were significantly larger than the B16-neo tumors (Fig. 6C). These findings indicate that MUC1 expression suppresses tumor growth in vivo.
smaller than the B16-neo tumors, and the average weight of B16-MUC1 tumors (0.08±0.05 g) was significantly lower than that of the B16-neo tumors (0.39±0.03 g) (Fig. 7A and B) (P<0.01). To determine whether MUC1 was expressed in the tumors, immunofluorescence staining was performed. The results showed strong positive staining for MUC1 in the

Figure 6. Mucin 1 (MUC1) expression downregulates both cyclin D1 and c-Myc. (A) mRNA levels of MUC1, cyclin D1 and c-Myc were detected by reverse transcription-polymerase chain reaction (RT-PCR) and normalized to β-actin. (B) Cell lysates were analyzed by western blotting for the expression of MUC1, cyclin D1 and c-Myc. β-actin was used as a loading control. Bar charts represent the relative mRNA and protein levels calculated from the relative intensity ratio of cyclin D1/β-actin and c-Myc/β-actin. Data are expressed as the means ± SD of 3 independent experiments. *P<0.05, **P<0.01.

Figure 7. Mucin 1 (MUC1) expression inhibits tumor growth in BALB/c nude mice. B16-MUC1 and B16-neo cells (2x10⁶) were injected into the right flank of BALB/c nude mice to form subcutaneous tumors. On day 12 post injection, tumors were removed, weighed and photographed. (A) An image showing tumor sizes in the B16-MUC1 and B16-neo groups. (B) The scatter diagram represents the tumor weight as analyzed by GraphPad Prism 5 software. The lines represent the means ± SD; **P<0.01. (C) MUC1 expression in tumor sections was detected by immunofluorescence staining with the anti-MUC1 primary antibody (GP1.4) and PE-conjugated secondary antibody (red). Nuclei were stained with DAPI (blue).
B16-MUC1 tumors, while no MUC1 expression was detected in the B16-neo tumors (Fig. 7C). These results indicate that MUC1 expression in B16 cells significantly suppressed tumor growth in a BALB/c nude mouse transplant tumor model.

Discussion

In the present study, we investigated the effects of MUC1 on malignancy behavior both in vitro and in vivo by stable expression of human full-length MUC1 in the B16 mouse melanoma cell line. We established two MUC1-positive clones, B16-MUC1 9-12 and B16-MUC1 9-23, and one empty vector control clone, B16-neo. These cells were characterized in vitro for MUC1 expression, cell proliferation, cell cycle distribution, migration and invasion and evaluated in vivo for the effects of MUC1 expression on tumor growth in a mouse transplant tumor model.

We found that MUC1 expression in B16 cells significantly inhibited cell proliferation and induced cell cycle arrest. These results conflict with most previous reports showing that MUC1 is an oncogene (31-33). However, this is not the only report demonstrating that MUC1 expression is associated with inhibited cell proliferation; several published studies have shown similar results (29,30). We also found that migration and invasion of B16-MUC1 cells were significantly decreased compared to B16 and B16-neo cells, opposing previous findings that MUC1 overexpression is associated with increased cell migration and invasion in breast, lung and pancreatic carcinoma cell lines (34,35).

Several published studies have shown that the MUC1-CT can interact with β-catenin to form a complex that contributes to tumorigenesis and tumor progression (36,37). Our present study showed that expression of the human full-length MUC1 in B16 cells increased the cytoplasmic levels of β-catenin, but reduced nuclear translocation of β-catenin and decreased cell proliferation. These results are similar to those described by Lillegård et al (38), who showed that overexpression of MUC1 in HEK293T cells decreased the nuclear levels of β-catenin and inhibited cell proliferation. Cyclin D1 and c-Myc are two important transcriptional targets of the Wnt/β-catenin pathway (39-41), both of which are involved in regulating cell cycle progression and promoting cellular proliferation and transformation. In our studies, MUC1 expression in B16 cells decreased the levels of nuclear β-catenin, reduced the activity of TCF, downregulated the expression of cyclin D1 and c-Myc and arrested the cell cycle at G1 phase. These results may provide a possible mechanistic explanation for how MUC1 expression decreased the proliferation of B16 cells in vitro. E-cadherin is a cell adhesion molecule that forms a complex with β-catenin and contributes to cell-cell adhesion (42), thereby preventing cell migration and invasion. Therefore, we examined the expression of E-cadherin in B16-MUC1, B16-neo and B16 cells. The results showed that E-cadherin expression was slightly increased in cells expressing MUC1 compared with the control cells, although the data did not reach statistical significance. These results suggest that the inhibition of cell migration and invasion may be associated with the upregulation of E-cadherin.

To investigate the effects of expressing human full-length MUC1 in B16 cells on tumorigenesis and tumor progression in vivo, a tumor growth assay was performed using BALB/c nude mice. We observed a strong reduction in the growth of B16-MUC1 tumors when compared with B16-neo tumors (Fig. 7A and B). These results agreed with the in vitro cell proliferation assays, suggesting that the decreased growth of MUC1-expressing primary tumors in nude mice is primarily due to decreased proliferative activity of the cells themselves. Premaratne et al (43) demonstrated that MUC1 expression in the prostate cancer cell line C4-2B4 had similar results. These findings suggest that MUC1 expression in the two types of cell lines displayed a negative effect on tumor growth, opposing most previous reports that MUC1 acts as an oncoprotein. Currently, there is no exact regulatory molecular mechanism to explain the conflicting data generated in different laboratories. Hattrup and Gendler (29) cautioned against overgeneralization of the results from individual cell lines on MUC1-mediated cancer progression since the functional regulation of MUC1 in different cell lines may vary depending on diverse factors such as cell type and signaling context.

In addition, it is frequently assumed that the MUC1-CT functions as an oncogene, but the effect of the MUC1-N in cell transformation and tumorigenesis is not yet clear. Several reports show that the variable number tandem repeat (VNTR)-containing extracellular domain of MUC1 regulates the transcription of several genes (44), providing a new insight for understanding the function of MUC1-N. In a study conducted by Lillehoj et al (38), an engineered variant of the MUC1-CT, CD8/MUC1, that lacks the VNTR-containing extracellular domain was transfected into HEK293 cells resulting in decreased cell proliferation. In our study, we obtained similar results. Although we transfected full-length human MUC1 into B16 cells, it may merely be equivalent to transfection of the mouse MUC1-CT, since the homology with the human protein is only 34% in the extracellular tandem repeat domain, whereas it is 87% in the transmembrane and cytoplasmic domains (45). Moreover, the MUC1-CT is identical in normal and tumor cells. Based on these findings, we propose that the VNTR-containing extracellular domain of MUC1 may play an important role in regulating the tumor-promoting effects in various types of cancers, but further studies are needed.

In summary, we demonstrated that MUC1 expression in B16 cells inhibited cell proliferation, migration and invasion and suppressed tumor growth in a mouse transplant tumor model. These results may be associated with several MUC1-related molecules of the β-catenin signaling pathway. It is suggested that the regulatory mechanisms of MUC1 as an oncoprotein are more complex than previously appreciated, which reinforces the importance of understanding alternative mechanisms that may regulate MUC1.

Acknowledgements

We would like to thank Dr O.J. Finn for the pcDNA3-MUC1 plasmid, which was used to transfect the B16 cell line. This study was supported by grants from the China National Natural Science Foundation (no. 30977282) and the Major Development Programs for New Drugs of the Chinese Academy of Sciences during the 12th Five-Year Plan Period (no. 2011ZX09102-001-36).
References